About this trial
Preservatives such as m-Cresol are essential components in many subcutaneously injected medications, including insulin or human growth hormone, to prevent bacterial growth. However, clinical reports have suggested that these preservatives may cause local discomfort or pain at the injection site, which can negatively impact treatment adherence. While m-Cresol is widely used, its direct contribution to injection-site pain has not yet been investigated in a prospective clinical trial.
This study aims to investigate whether subcutaneous injection of m-Cresol at concentrations commonly used in clinical practice (0.1% and 0.25%) cause significantly more pain than a preservative-free control solution. In a randomized, double-blind crossover design, healthy volunteers will receive three separate injections in a belly fold. Participants will rate their pain every 5 seconds until it subsides. The findings will help determine if m-Cresol is a primary source of injection-site pain and could lead to the development of more comfortable drug formulations.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Age between 18 and 70 years
Full legal capacity
Disqualifiers
Participant of another study, ongoing or within the last four weeks
Current medication intake (except hormonal contraception) or drug abuse
Female subjects: Positive pregnancy test or breastfeeding
Body temperature above 38°C, verified by infrared thermometer
Trial design
Crossover
Treatments tested in this trial
m-Cresol 0.1%
Other interventionA preservative administered subcutaneously at 0.1%, a common concentration used in medicines.
m-Cresol 0.25%
Other interventionA preservative administered subcutaneously at 0.25%, a common concentration used in medicines.
Control Solution
Other interventionA control solution administered subcutaneously.
Treatment groups
Trial outcomes
Primary outcomes
Area Under the Curve (AUC) of Pain Intensity
Total pain burden calculated as the Area Under the Curve of serial pain ratings (0-100 numerical pain rating scale) recorded every 5 seconds from the start of injection until no pain is reported for 30 seconds.
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: